Important notice: This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that must be evaluated, prescribed, and monitored by a licensed healthcare professional. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Eligibility for any prescription program is determined solely by a licensed clinician. Always consult your healthcare provider before starting any medication or weight management program.
What Is Wellorithm?
Wellorithm is a telehealth weight management platform that connects patients with licensed U.S. clinicians for evaluation and, when medically appropriate, prescription access to compounded GLP-1 medications. The platform does not dispense medication itself — it coordinates between an independent clinical layer and licensed U.S. pharmacy partners, a three-entity structure standard across telehealth weight management services.
Understanding that structure matters before evaluating any telehealth program. Wellorithm is the technology platform. Clinical decisions belong to the independent licensed providers. Medication is dispensed by licensed compounding pharmacies. These are three distinct functions, and each operates under its own regulatory framework.
For a broader overview of how GLP-1 telehealth platforms are structured and evaluated, see our telehealth platform reviews index, which covers multiple programs in this category. For a full review of Wellorithm's pricing, refund policy, and program terms, see our Wellorithm review.
The Compounding Distinction: What It Means for Patients
Wellorithm's program centers on compounded GLP-1 medications. This distinction carries specific regulatory and clinical implications that every prospective patient should understand before enrolling.
Semaglutide is the active ingredient in FDA-approved brand-name products including Wegovy and Ozempic. Tirzepatide is the active ingredient in FDA-approved products including Mounjaro and Zepbound. The compounded versions available through platforms like Wellorithm are prepared by licensed compounding pharmacies based on individual prescriptions — but the finished compounded product has not undergone the same FDA approval process as the brand-name drugs.
As Wellorithm's own website states: compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. The prescribing clinician makes the determination of whether a compounded option is appropriate for each individual patient.
The legal landscape for compounded GLP-1 medications has also been directly tied to FDA drug shortage designations. Federal compounding regulations restrict the production of compounded drugs that are essentially a copy of commercially available FDA-approved products, and enforcement discretion tied to GLP-1 shortage status has been an active and evolving area for semaglutide and tirzepatide specifically. The availability of compounded GLP-1 medications through any telehealth platform can change depending on current FDA shortage designation — confirm current availability directly with Wellorithm before enrolling.
How the Wellorithm Process Works
Wellorithm describes a four-stage process for patients moving from inquiry to treatment. Each stage involves a distinct action and expected outcome.
Stage one: Account creation and health questionnaire. Patients sign up online and complete a digital health assessment that covers medical history, current medications, weight history, and relevant health conditions. The accuracy of information provided at this stage directly affects the clinical evaluation that follows — all disclosures should be complete and accurate.
Stage two: Virtual clinician consultation. A licensed clinician reviews the submitted health information and conducts a virtual consultation. The clinician evaluates whether GLP-1 therapy may be appropriate based on the patient's profile. Eligibility criteria for GLP-1 medications typically include a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition — though the prescribing clinician makes the final determination based on the full clinical picture.
Stage three: Prescription and medication delivery. If the clinician determines a prescription is appropriate, the prescription is sent to a licensed U.S. pharmacy partner. Medication is then shipped directly to the patient's home. Delivery timelines depend on pharmacy processing and logistics.
Stage four: Ongoing support and monitoring. Wellorithm states that support is available 24 hours a day, seven days a week, by phone at +1 (877) 402-6778. Ongoing monitoring and plan adjustments are described as part of the program.
Medication Options Available Through Wellorithm
According to the official Wellorithm website, the platform offers four compounded medication pathways. All are prescription-only and subject to clinician approval.
Compounded Semaglutide Injection: A once-weekly injectable formulation using semaglutide as the active ingredient. Semaglutide is a GLP-1 receptor agonist that works by mimicking the GLP-1 hormone, which regulates appetite signaling, gastric emptying, and insulin secretion. Clinical trial data published in peer-reviewed literature — including the STEP trials — demonstrated meaningful weight reduction in adults with obesity when semaglutide was used alongside lifestyle interventions, though trial populations and conditions differ from real-world telehealth settings and individual outcomes vary.
Compounded Tirzepatide Injection: A once-weekly injectable formulation using tirzepatide, which acts on both GLP-1 and GIP receptors — a dual incretin mechanism. Published clinical trial data from the SURMOUNT trials showed pronounced average effects on body weight in certain trial populations; individual outcomes in real-world settings vary widely and are not guaranteed.
Compounded Semaglutide Oral Dissolving Tablets: An oral alternative for patients for whom injectable formulations are not preferred, subject to clinician evaluation and prescribing appropriateness.
Compounded Tirzepatide Oral Dissolving Tablets: An oral alternative using tirzepatide, also subject to clinician evaluation.
None of these are FDA-approved finished drug products. They are compounded formulations prepared by licensed pharmacies based on individual prescriptions. The clinician who evaluates your case will determine which option, if any, is appropriate for your health profile.
How GLP-1 Medications Work: The Mechanism
GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone naturally released by the gastrointestinal tract in response to food intake. The mechanism involves several overlapping effects relevant to weight management.
GLP-1 receptors are found in the hypothalamus, a region of the brain involved in appetite regulation. Activation of these receptors reduces appetite signaling and increases satiety — the sense of fullness. GLP-1 also slows gastric emptying, meaning food moves more slowly from the stomach to the small intestine, which extends the physiological sense of fullness after a meal. On the metabolic side, GLP-1 stimulates insulin secretion in response to elevated blood glucose and suppresses glucagon, supporting glycemic control.
Tirzepatide adds a second mechanism: activation of GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP also plays a role in insulin secretion and has been studied for its effects on adipose tissue metabolism. The dual-receptor mechanism is the basis for the comparison between semaglutide and tirzepatide as weight management agents — a topic covered in depth in our Wellorithm semaglutide breakdown.
Who May Be Eligible
The published clinical guidelines for GLP-1 prescription weight management typically identify two primary eligibility criteria: a BMI of 30 or higher (classified as obesity), or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. These are the criteria reflected in FDA-approved labeling for GLP-1 weight management medications and are the standard framework used by telehealth platforms operating in this space.
Wellorithm's FAQ states that eligibility is determined by the clinician following a medical evaluation. Prescription treatment is not guaranteed. Certain medical conditions may disqualify a patient from GLP-1 therapy regardless of BMI, including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis. Complete and accurate disclosure during the intake process is essential for the clinician to make an appropriate assessment.
Pricing Structure
According to the official Wellorithm website, published starting prices are $147 for compounded semaglutide and $249 for compounded tirzepatide. Membership fees are billed on a recurring 28-day cycle. These are starting prices — actual costs depend on dosage and plan selected. Wellorithm's program operates on a cash-pay basis. Insurance is generally not billed directly; coverage or reimbursement depends on your individual plan. Always verify current pricing directly on the official website before enrolling, as pricing is subject to change.
What to Confirm Before You Enroll
Before committing to any telehealth GLP-1 program, the following questions are worth confirming directly with Wellorithm or with your own healthcare provider. Is the platform currently operating in your state — Wellorithm serves 49 states, with Louisiana currently excluded. What is the current pricing for the specific medication and dosage the clinician is likely to prescribe — starting prices reflect the lowest tier. What is the exact refund and cancellation policy — published terms state payments are non-refundable once processed, and cancellation is handled by contacting support via email. What pharmacy will dispense your medication, and what is that pharmacy's compounding compliance status. What follow-up and monitoring does the program include after the initial prescription.
For a complete evaluation of Wellorithm's program terms, pricing structure, and how it compares to similar platforms, see the full Wellorithm review and our weight management research hub.
Frequently Asked Questions
What is Wellorithm? Wellorithm is a telehealth weight management platform that connects eligible patients with licensed clinicians for evaluation and, when medically appropriate, prescription access to compounded GLP-1 medications such as semaglutide or tirzepatide. Compounded medications from this platform have not been reviewed or approved by the FDA for safety, effectiveness, or quality.
How does the Wellorithm intake process work? Patients complete a brief online health questionnaire, connect with a licensed clinician via virtual consultation, and — if the clinician determines a prescription is appropriate — receive medication shipped from a licensed U.S. pharmacy. Eligibility is not guaranteed.
What medications does Wellorithm offer? According to the official Wellorithm website, the platform offers compounded semaglutide injections, compounded tirzepatide injections, compounded semaglutide oral dissolving tablets, and compounded tirzepatide oral dissolving tablets. These are compounded formulations, not FDA-approved brand-name products.
Is Wellorithm available in all states? Per Wellorithm's published FAQ, the platform serves 49 U.S. states. Louisiana is currently excluded. Services are not available outside the United States.
Does Wellorithm accept insurance? According to Wellorithm's published terms, the program operates on a cash-pay basis. Insurance is generally not billed directly. Coverage or reimbursement, if any, depends on the individual plan — confirm with your insurer before enrolling.